Hi all
pretty new to all this. I have pumped some into Deltex - looks like a strong product with good growth. Could be a steady gainer.
Does anyone else have this, and anyone have some research on it? Someone with more experience than me!
thanks in advance.
Grajul

Early in the day yet, but Level 2 looking good, about to tick up.
End of day should be interesting.

Deltex Medical Plc.. Preliminary results for the year ended 31 December 2006

Financial Highlights

Turnover increased by 15% to pound;3,511,000 with 80% of growth from recurring revenue streams
Operating losses increase to pound;2,102,000 (2005: pound;1,774,000) after TECO acquisition and restructuring of European distribution network
Cash of pound;418,000 with a further pound;465,000 of new equity raised since year end
Company enters 2007 with lowest rate of cash burn and operating loss
since first listing

Operating Highlights

All regions show sustainable growth driven by recurring probe revenues
Steady stream of evidenced based research supports new monitoring
applications
SupraQ adopted by Medway Maritime Hospital for critical care
applications; enhanced prototype SupraQ completed in 2007
Accelerating uptake from a range of reference customers including
European teaching hospitals and US military
Medicare proposed reimbursement approval lays ground for accelerated
penetration of USA
Company configured for growth in all its key markets

For the reader of this thread a full report on view at www.sharecluuk.co.uk

Looks like Charles Stanley & Co Ltd (Rock Nominees Limited) are now on board with 4,851,121 a 5.8% stake. Surprised the sp is down ,although have not seen the budget yet so don't know if that has had any effect or not.

Looks like the todays news release is just reaffirming in simple speak what the very lengthy document of last week was telling us. CardioQ is good for the patient.
SP did not move on this release due to I expect, punters treating it as yet another positive result. When the medical world wakes up to this excellent piece of kit, no doubt the investors will also. Staying well into this share for that almost certain take off day.

Hi greekman

Key conclusions from the US report

The HTA concluded that in 'patients undergoing surgical procedures with an
expected substantial blood loss or fluid compartment shifts requiring fluid
replacement' the clinical evidence for ODM was strong in respect of the
following three statements:

1. 'Doppler-guided fluid replacement during surgery leads to a clinically
significant reduction in major complications';

2. 'Doppler-guided fluid replacement during surgery leads to a clinically
significant reduction in the total number of complications'; and

3. 'Doppler-monitored fluid replacement leads to a reduction in hospital
stay'.

The full report and other news can be found at www.shareclubuk.co.uk for members and others to view.. Over the next few weeks the S.P. should firm up. This US report will help matters along

Evening Myway,

No wonder these medical devices take so long to really get going.
From the 166 page document release last week your summary states just about all we wanted to know.
As said many times lately, when this takes off nothing will stop it.
If a rival does show up on yon distant horizon just think how far they will have to go to obtain as many pro trial reports as the CardioQ.
Deltex are in a very strong position.

Time to top up, me thinks!

Yes it may well be Neil, but this is still all rather disappointing.
2517

Very frustrating! but we may not see this level again perhaps.

They say no news is good news, but as far as Deltex are concerned we keep seeing good reports leading us to believe good news re contracts are round the corner. So when there is no news, disappointment sets in with that added problem of expectations not coming to fruition, resulting in the sp dropping.
Not the fault of Deltex, just how the market, quite naturally reacts.
Patience my fellow investors, patience.

Just a recap on what Nigel Keen, Chairman of Deltex Medical, said: 15th March 07.

"2006 has been a year of transformation for Deltex Medical. Since receiving
endorsements for our CardioQ product from the Freeman study, we have seen
accelerated deployment of the product in active use - particularly in operating theatres. Product deployment is driving probe sales and further endorsement by leading medical institutions, in the UK, Continental Europe and the USA is laying a solid foundation for growth across all our key markets for 2007 and beyond."

The business is now trading across the board UK. Euro and the USA.

Hi Greekman and everyone... Deltex has the goods, the City will soon wake up..

Have a good Easter.

myway

Thanks Myway,

Same to everyone.

Fantastic, no figures yet but this must be the start of something realy big.

Comments such as.....First hospital in the world to
make the use of Deltex Medical's CardioQ monitor standard clinical practice for
a wide range of major surgery.

Will become standard clinical practice over the coming months.

A growing number of hospitals in the UK and abroad plan to introduce similar
enhanced recovery or fast-track surgical programmers.

Our patience looks like paying off, in the not too distant future.

Good news!
Hopefully now a long and steady climb.

First class news this morning from Deltex Medical, the headline news:- Major London Teaching Hospital makes CardioQ(TM) standard clinical practice for
major surgery. University College London Hospital ('UCLH') has become the first hospital in the world to make the use of Deltex Medical's CardioQ monitor standard clinical practice for a wide range of major surgery.

At last hospitals have began to notice that CardioQ is cost effective, UCLH expects the programme to 'cut by more than half the recovery time for patients undergoing major surgery across a wide range of specialties. This will in turn reduce the millions of pounds spent by the NHS on keeping patients in hospital beds unnecessarily.

Others will soon follow. The full report is display at shareclubuk over the last few days I have noted that the share price has move up, this morning news move the price up by 1.50p or 8.33%.

Would not be too surprised to see only a slow steady climb.
Due to the many previous reports, and small contracts, what this share really need is a big buy from the institutions. Due to the previous influx of news, not upping the Sp much, procrastination has set in.
We need the financial media to grab a hold and only then will Deltex get onto the investors radar.
When oh when will the market wake up to this shares real potential.

It is frustrating! what i do is srceam in a pillow every now and then.
works for me!
On a serious note however, i think adoption may take longer than we would like.
Same old issues applying, but they will get there...............in the end.

The important bits to me were, "monitor standard clinical practice for
a wide range of major surgery/will become standard clinical practice over the coming months". Prof Singer is well respected in his field (I read it somewhere in a medical paper) and the UCLH has been the forerunner of several medical enhancements. The thing is will the markets, see it that way.
Just to ADD. There are 6 hospitals in the UCLH trust, specializing in several areas, which as far as Deltex are concerned is no bad thing.
University College Hospital..

Hospital for Tropical Diseases
National Hospital for Neurology & Neurosurgery
Elizabeth Garrett Anderson & Obstetric Hospital
Eastman Dental Hospital
The Royal London Homoeopathic Hospital
The Heart Hospital

OK using the CardioQ in dentistry is perhaps pushing it, but if word speads from these other hospitals, who knows where this will be in 12 months.

My comment Great News may be a bit OTT. Perhaps I let my enthusiasm get the better of me.
Time will tell as they say.

Homeopathic? Really??????? Are you really really REALLY sure of that one?

"Homeopathic" involves diluting things by factors of millions or more.

However, it is a good announcement. UCLH is a teaching hospital so where it leads, others will follow. They are blazing a trail for the rest of the NHS. This is fantastic news for Deltex. We're likely to see more of this sort of announcement over the coming year.